June 28, 2016
(Medscape) – The US Food and Drug Administration (FDA) has approved the combination drug of sofosbuvir and velpatasvir (Epclusa, Gilead Sciences) for adults with chronic hepatitis C virus (HCV) infection, the first one to treat all six major genotypes of the infection, the agency announced today. The new drug’s broad coverage could make it a one-size-fits-all therapy suitable for primary care. Gilead Sciences President and CEO John Gilliland said in a news release that sofosbuvir/velpatasvir could eliminate the need for genotype testing, “which can be a barrier to treatment in certain resource-constrained settings.”
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.